| HOME >> BIOLOGY >> TECHNOLOGY |
BOTHELL, Wash., March 1, 2011 /PRNewswire/ -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated at WellStar Health System in Marietta and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths. Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion.Warfarin is prescribed to 2 million patients in the U.S. annually and approximately 20 million Americans use the drug in total. Warfarin is difficult to dose as patients respond to it differently according to their genetic makeup – too much warfarin can result in severe bleeding, and too little can cause clot formation and increased risk of stroke. In the past, warfarin dosing relied on trial-and-error, which exposed patients to serious medical risks. Warfarin is the second most frequent cause of drug-related emergency room visits.
"Georgia is a committed partner in advancing personalized medicine, and we are proud to be the testing ground for research that has the potential to improve health, save lives and lower healthcare costs here in Georgia as well as nationwide," said Chris Cummiskey, Commissioner of the Georgia Department of Economic Development.
Over the past few years, two genetic variants have been identified that predict an individual's response to warfarin. Using genetic testing to guide physicians in starting warfarin therapy has
'/>"/>
| SOURCE Iverson Genetic Diagnostics, Inc. Copyright©2010 PR Newswire. All rights reserved |